Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407

The druggable genome

Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305

Discovering High-Affinity Ligands for Proteins: SAR by NMR

Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,045

Reaching for high-hanging fruit in drug discovery at protein–protein interfaces

Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 2,002

Anatomy of hot spots in protein interfaces

Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988

A Hot Spot of Binding Energy in a Hormone-Receptor Interface

Clackson, T., & Wells, J. A. (1995) · Science · doi:10.1126/science.7529940 · Cited by 1,987

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

Schindler, T. H., Bornmann, W. G., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,785

Fpocket: An open source platform for ligand pocket detection

Guilloux, V. L., Schmidtke, P., & Tufféry, P. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-168 · Cited by 1,724

X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death

Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D. G., Chang, B. S., Thompson, C. B., Wong, S., et al. (1996) · Nature · doi:10.1038/381335a0 · Cited by 1,467

Role of Molecular Dynamics and Related Methods in Drug Discovery

Vivo, M. D., Masetti, M., Bottegoni, G., & Cavalli, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01684 · Cited by 1,358

Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates

Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835

Inhibition of α-helix-mediated protein–protein interactions using designed molecules

Azzarito, V., Long, K., Murphy, N. S., & Wilson, A. J. (2013) · Nature Chemistry · doi:10.1038/nchem.1568 · Cited by 727

Discovery of small molecule cancer drugs: Successes, challenges and opportunities

Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 591

Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?

Giordanetto, F., & Kihlberg, J. O. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400887j · Cited by 577

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Cromm, P. M., & Crews, C. M. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.05.024 · Cited by 428

Unexplored therapeutic opportunities in the human genome

Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378

How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets

Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. O. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 348

Erratum: Unexplored therapeutic opportunities in the human genome

Oprea, T. I., Bologa, C., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.52 · Cited by 303

Cell permeability beyond the rule of 5

Matsson, P., Doak, B. C., Over, B., & Kihlberg, J. O. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.013 · Cited by 305

Modulators of 14-3-3 Protein–Protein Interactions

Stevers, L. M., Sijbesma, E., Botta, M., MacKintosh, C., Obšil, T., Landrieu, I., Cau, Y., Wilson, A. J., Karawajczyk, A., Eickhoff, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00574 · Cited by 295

Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors

Lagorce, D., Douguet, D., Miteva, M. A., & Villoutreix, B. O. (2017) · Scientific Reports · doi:10.1038/srep46277 · Cited by 278

Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5

Sebastiano, M. R., Doak, B. C., Backlund, M., Poongavanam, V., Over, B., Ermondi, G., Caron, G., Matsson, P., & Kihlberg, J. O. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00347 · Cited by 242

Applications of Connectivity Map in drug discovery and development

Qu, X. A., & Rajpal, D. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.017 · Cited by 235

Improving target assessment in biomedical research: the GOT-IT recommendations

Emmerich, C. H., Martinez‐Gamboa, L., Hofmann, M. C. J., Bonin, M., Arbach, O., Schendel, P., Gerlach, B., Hempel, K., Bespalov, A., Dirnagl, U., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0087-3 · Cited by 243

Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation

Bond, M. J., & Crews, C. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00011j · Cited by 232

Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations

Oleinikovas, V., Saladino, G., Cossins, B. P., & Gervasio, F. L. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b05425 · Cited by 231

Structural and conformational determinants of macrocycle cell permeability

Over, B., Matsson, P., Tyrchan, C., Artursson, P., Doak, B. C., Foley, M. A., Hilgendorf, C., Johnston, S. E., Lee, M. D., Lewis, R. J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2203 · Cited by 209

Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein Interface

Molle, I. V., Thomann, A., Buckley, D. L., So, E. C., Lang, S., Crews, C. M., & Ciulli, A. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.08.015 · Cited by 203

Mitigating risk in academic preclinical drug discovery

Dahlin, J. L., Inglese, J., & Walters, M. A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4578 · Cited by 192

Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles

Tang, J. P., & Aittokallio, T. A. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990470 · Cited by 187

Drug discovery beyond the rule of 5 - Opportunities and challenges

Doak, B. C., & Kihlberg, J. O. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1264385 · Cited by 149

Objective assessment of cancer genes for drug discovery

Patel, M. N., Halling‐Brown, M., Tym, J. E., Workman, P., & Al‐Lazikani, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3913 · Cited by 133

Solution Conformations Explain the Chameleonic Behaviour of Macrocyclic Drugs

Danelius, E., Poongavanam, V., Peintner, S., Wieske, L. H. E., Erdélyi, M., & Kihlberg, J. O. (2020) · Chemistry - A European Journal · doi:10.1002/chem.201905599 · Cited by 131

Targeting Mycobacterium tuberculosis nucleoid-associated protein HU with structure-based inhibitors

Bhowmick, T., Ghosh, S., Dixit, K., Ganesan, V., Ramagopal, U. A., Dey, D., Sarma, S. P., Ramakumar, S., & Nagaraja, V. (2014) · Nature Communications · doi:10.1038/ncomms5124 · Cited by 116

The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation

Lee, H., Li, C., Ruan, D., Powers, S., Thompson, P. A., Frohman, M. A., & Chan, C. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.08.009 · Cited by 114

Drug‐Like ProteinProtein Interaction Modulators: Challenges and Opportunities for Drug Discovery and Chemical Biology

Villoutreix, B. O., Kuenemann, M. A., Poyet, J., Bruzzoni‐Giovanelli, H., Labbé, C. M., Lagorce, D., Spérandio, O., & Miteva, M. A. (2014) · Molecular Informatics · doi:10.1002/minf.201400040 · Cited by 118

Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth

Wang, H., Wang, L., Zhang, Y., Wang, J., Deng, Y., & Lin, D. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0280-y · Cited by 113

Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space

Poongavanam, V., Doak, B. C., & Kihlberg, J. O. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.010 · Cited by 97

Fine-Tuning Multiprotein Complexes Using Small Molecules

Thompson, A. D., Dugan, A. E., Gestwicki, J. E., & Mapp, A. K. (2012) · ACS Chemical Biology · doi:10.1021/cb300255p · Cited by 98

Conformational Sampling of Macrocyclic Drugs in Different Environments: Can We Find the Relevant Conformations?

Poongavanam, V., Danelius, E., Peintner, S., Alcaraz, L., Caron, G., Cummings, M. D., Wlodek, S. T., Erdélyi, M., Hawkins, P. C. D., Ermondi, G., et al. (2018) · ACS Omega · doi:10.1021/acsomega.8b01379 · Cited by 91

Discovery of Small Molecules that Inhibit the Disordered Protein, p27Kip1

Iconaru, L. I., Ban, D., Bharatham, K., Ramanathan, A., Zhang, W., Shelat, A. A., Zuo, J., & Kriwacki, R. W. (2015) · Scientific Reports · doi:10.1038/srep15686 · Cited by 93

Global vision of druggability issues: applications and perspectives

Hussein, H. A., Geneix, C., Petitjean, M., Borrel, A., Flatters, D., & Camproux, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.021 · Cited by 93

Small-molecule inhibitors that disrupt the MTDH–SND1 complex suppress breast cancer progression and metastasis

Shen, M., Wei, Y., Kim, H., Wan, L., Jiang, Y., Hang, X., Raba, M., Remiszewski, S., Rowicki, M., Wu, C.-G., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00279-5 · Cited by 83

Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma

Purzner, T., Purzner, J., Buckstaff, T. M., Cozza, G., Gholamin, S., Rusert, J. M., Hartl, T. A., Sanders, J., Conley, N. R., Ge, X., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aau5147 · Cited by 80

14-3-3 Proteins: Novel Pharmacological Targets in Neurodegenerative Diseases

Pair, F. S., & Yacoubian, T. A. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.01.001 · Cited by 74

Allosteric Inhibition of a Semaphorin 4D Receptor Plexin B1 by a High-Affinity Macrocyclic Peptide

Matsunaga, Y., Bashiruddin, N. K., Kitago, Y., Takagi, J., & Suga, H. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.09.015 · Cited by 74

High‐Throughput Kinetic Analysis for Target‐Directed Covalent Ligand Discovery

Craven, G. B., Affron, D. P., Allen, C. E., Matthies, S., Greener, J. G., Morgan, R. M. L., Tate, E. W., Armstrong, A., & Mann, D. J. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201711825 · Cited by 73

Amorphous solid dispersions: Utilization and challenges in preclinical drug development within AstraZeneca

Anane‐Adjei, A. B., Jacobs, E., Nash, S. C., Askin, S., Soundararajan, R., Kyobula, M., Booth, J., & Campbell, A. D. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121387 · Cited by 73

NMR approaches in structure-based lead discovery: Recent developments and new frontiers for targeting multi-protein complexes

Dias, D. M. G., & Ciulli, A. (2014) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2014.08.012 · Cited by 77

Small‐Molecule Proteomimetic Inhibitors of the HIF‐1α–p300 Protein–Protein Interaction

Burslem, G. M., Kyle, H. F., Breeze, A. L., Edwards, T. A., Nelson, A. S., Warriner, S. L., & Wilson, A. J. (2014) · ChemBioChem · doi:10.1002/cbic.201400009 · Cited by 70

A Leap into the Chemical Space of Protein-Protein Interaction Inhibitors

Villoutreix, B. O., Labbé, C. M., Lagorce, D., Laconde, G., & Spérandio, O. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802651571 · Cited by 72

K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

Hofmann, I., Weiss, A., Elain, G., Schwaederle, M. C., Sterker, D., Romanet, V., Schmelzle, T., Lai, A., Brachmann, S. M., Bentires‐Alj, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044146 · Cited by 69

Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions?

Dias, D. M. G., Molle, I. V., Baud, M. G. J., Galdeano, C., Geraldes, C. F. G. C., & Ciulli, A. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400296c · Cited by 62

A Chemical Inhibitor of the Skp2/p300 Interaction that Promotes p53‐Mediated Apoptosis

Oh, M., Lee, J. H., Moon, H., Hyun, Y.-J., & Lim, H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201508716 · Cited by 62

In silico design of low molecular weight protein–protein interaction inhibitors: Overall concept and recent advances

Kuenemann, M. A., Spérandio, O., Labbé, C. M., Lagorce, D., Miteva, M. A., & Villoutreix, B. O. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.02.006 · Cited by 64

Ultra-High-Throughput Structure-Based Virtual Screening for Small-Molecule Inhibitors of Protein–Protein Interactions

Johnson, D. K., & Karanicolas, J. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00572 · Cited by 70

Drug Syntheses Beyond the Rule of 5

Tyagi, M., Begnini, F., Poongavanam, V., Doak, B. C., & Kihlberg, J. O. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201902716 · Cited by 58

Modulating Protein-Protein Interactions: From Structural Determinants of Binding to Druggability Prediction to Application

Metz, A., Ciglia, E., & Gohlke, H. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802651553 · Cited by 59

Monosubstituted alkenyl amino acids for peptide “stapling”

Yeo, D. J., Warriner, S. L., & Wilson, A. J. (2013) · Chemical Communications · doi:10.1039/c3cc45231j · Cited by 56

PAF-Mediated MAPK Signaling Hyperactivation via LAMTOR3 Induces Pancreatic Tumorigenesis

Jun, S., Lee, S., Kim, H.-C., Ng, C., Schneider, A. M., Ji, H. L., Ying, H., Wang, H., DePinho, R. A., & Park, J. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.026 · Cited by 76

Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells

Zhao, C., Xiao, H., Wu, X., Li, C., Liang, G., Yang, S., & Lin, J. (2015) · Oncotarget · doi:10.18632/oncotarget.3991 · Cited by 51

Exploring the dark genome: implications for precision medicine

Oprea, T. I. (2019) · Mammalian Genome · doi:10.1007/s00335-019-09809-0 · Cited by 47

Mining Natural Products for Macrocycles to Drug Difficult Targets

Begnini, F., Poongavanam, V., Over, B., Castaldo, M., Geschwindner, S., Johansson, P., Tyagi, M., Tyrchan, C., Wissler, L., Sjö, P., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01569 · Cited by 50

Use of augmented reality (AR) to aid bioscience education and enrich student experience

Reeves, L., Bolton, E., Bulpitt, M., Scott, A., Tomey, I., Gates, M., & Baldock, R. A. (2021) · Research in Learning Technology · doi:10.25304/rlt.v29.2572 · Cited by 49

De novo coiled-coil peptides as scaffolds for disrupting protein–protein interactions

Fletcher, J. M., Horner, K. A., Bartlett, G. J., Rhys, G. G., Wilson, A. J., & Woolfson, D. N. (2018) · Chemical Science · doi:10.1039/c8sc02643b · Cited by 51

Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators

Bustad, H. J., Kallio, J. P., Vorland, M., Fiorentino, V., Sandberg, S., Schmitt, C., Aarsand, A. K., & Martı́nez, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020675 · Cited by 49

Modulating Protein–Protein Interactions with Visible‐Light‐Responsive Peptide Backbone Photoswitches

Albert, L., Peñalver, A., Djoković, N., Werel, L., Hoffarth, M., Ružić, D., Xu, J., Essen, L., Nikolic, K. M., Dou, Y., et al. (2019) · ChemBioChem · doi:10.1002/cbic.201800737 · Cited by 47

The recent progress in proteochemometric modelling: focusing on target descriptors, cross-term descriptors and application scope

Qiu, T., Qiu, J., Feng, J., Wu, D., Yang, Y., Tang, K., Cao, Z., & Zhu, R. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw004 · Cited by 46

Chemical space of Escherichia coli dihydrofolate reductase inhibitors: New approaches for discovering novel drugs for old bugs

Srinivasan, B., Tonddast‐Navaei, S., Roy, A., Zhou, H., & Skolnick, J. (2018) · Medicinal Research Reviews · doi:10.1002/med.21538 · Cited by 46

Druggable Orthosteric and Allosteric Hot Spots to Target Protein-protein Interactions

Ma, B., & Nussinov, R. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990073 · Cited by 45

Contributions of the RAD51 N-terminal domain to BRCA2-RAD51 interaction

Subramanyam, S. V., Jones, W. T., Spies, M., & Spies, M. A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt691 · Cited by 44

Structural Systems Pharmacology: The Role of 3D Structures in Next-Generation Drug Development

Duran‐Frigola, M., Mosca, R., & Aloy, P. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.004 · Cited by 44

Scanning Protein Surfaces with DNA‐Encoded Libraries

Kunig, V. B. K., Potowski, M., Škopić, M. K., & Brunschweiger, A. (2020) · ChemMedChem · doi:10.1002/cmdc.202000869 · Cited by 44

Druggability Assessment in TRAPP Using Machine Learning Approaches

Yuan, J.-H., Han, S. B., Richter, S., Wade, R. C., & Kokh, D. B. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b01185 · Cited by 42

Structural Elucidation and Synthesis of Eudistidine A: An Unusual Polycyclic Marine Alkaloid that Blocks Interaction of the Protein Binding Domains of p300 and HIF-1α

Chan, S. T. S., Patel, P., Ransom, T. R., Henrich, C. J., McKee, T. C., Goey, A. K. L., Cook, K. M., Figg, W. D., McMahon, J. B., Schnermann, M. J., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b02156 · Cited by 41

Targeting SOST using a small-molecule compound retards breast cancer bone metastasis

Sun, L., Zhang, Y., Chen, G., Ji, Y., Ma, Q., Qiao, X., Wu, S., Zhou, L. M., Bu, J., Zhu, X., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01697-4 · Cited by 40

A Bifunctional Amino Acid Enables Both Covalent Chemical Capture and Isolation of in Vivo Protein–Protein Interactions

Joiner, C. M., Breen, M. E., Clayton, J., & Mapp, A. K. (2016) · ChemBioChem · doi:10.1002/cbic.201600578 · Cited by 40

Quantitative metrics for drug–target ligandability

Vukovič, S., & Huggins, D. J. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.02.015 · Cited by 40

Pyrimidine Triazole Thioether Derivatives as Toll‐Like Receptor 5 (TLR5)/Flagellin Complex Inhibitors

Yan, L., Liang, J., Yao, C., Wu, P., Zeng, X., Cheng, K., & Yin, H. H. (2015) · ChemMedChem · doi:10.1002/cmdc.201500471 · Cited by 39

Foldamers in Medicinal Chemistry

Pasco, M., Dolain, C., & Guichard, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12565-x · Cited by 42

Mechanism of Feedback Allosteric Inhibition of ATP Phosphoribosyltransferase

Pedreño‐López, S., Pisco, J. P., Larrouy-Maumus, G. J., Kelly, G. P., & de Carvalho, L. P. S. (2012) · Biochemistry · doi:10.1021/bi300808b · Cited by 37

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer

Awasthi, N., Monahan, S., Stefaniak, A., Schwarz, M. A., & Schwarz, R. E. (2017) · Oncotarget · doi:10.18632/oncotarget.23684 · Cited by 35

Exploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies

Kyle, H. F., Wickson, K. F., Stott, J., Burslem, G. M., Breeze, A. L., Tiede, C., Tomlinson, D. C., Warriner, S. L., Nelson, A. S., Wilson, A. J., et al. (2015) · Molecular BioSystems · doi:10.1039/c5mb00284b · Cited by 35

Exploring the role of water in molecular recognition: predicting protein ligandability using a combinatorial search of surface hydration sites

Vukovič, S., Brennan, P. E., & Huggins, D. J. (2016) · Journal of Physics Condensed Matter · doi:10.1088/0953-8984/28/34/344007 · Cited by 33

Proteome‐Wide Fragment‐Based Ligand and Target Discovery

Forrest, I., & Parker, C. G. (2023) · Israel Journal of Chemistry · doi:10.1002/ijch.202200098 · Cited by 31

Comparative pharmacokinetic profile of cyclosporine (CsA) with a decapeptide and a linear analogue

Price, D. A., Eng, H. F., Farley, K. A., Goetz, G. H., Huang, Y., Jiao, Z., Kalgutkar, A. S. S., Kablaoui, N. M., Khunte, B., Liras, S. I., et al. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob00096k · Cited by 33

Total Synthesis and Evaluation of B‐Homo Palmatine and Berberine Derivatives as p300 Histone Acetyltransferase Inhibitors

Yang, Z., Zhang, Y., Chen, X., Li, W., Li, G., & Wu, Y. (2018) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201701693 · Cited by 33

Understanding the Complexity of Epigenetic Target Space

Pande, V. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01507 · Cited by 32

Anti-infective activities of 11 plants species used in traditional medicine in Malaysia

Azman, N. S. N., Hossan, M. S., Nissapatorn, V., Uthaipibull, C., Prommana, P., Khoo, T.-J., Rahmatullah, M., Mahboob, T., Raju, C. S., Jindal, H. M., et al. (2018) · Experimental Parasitology · doi:10.1016/j.exppara.2018.09.020 · Cited by 32

Helix mimetics: Recent developments

Wilson, A. J. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.05.001 · Cited by 32

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31

Going Viral: An Investigation into the Chameleonic Behaviour of Antiviral Compounds

Wieske, L. H. E., Atilaw, Y., Poongavanam, V., Erdélyi, M., & Kihlberg, J. O. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202202798 · Cited by 30

Metal complexes as “protein surface mimetics”

Hewitt, S. H., & Wilson, A. J. (2016) · Chemical Communications · doi:10.1039/c6cc03457h · Cited by 29

Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises

Singh, N., & Villoutreix, B. O. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.059 · Cited by 26

An Insight into the Medicinal Chemistry Perspective of Macrocyclic Derivatives with Antitumor Activity: A Systematic Review

Liang, Y., Fang, R., & Rao, Q. (2022) · Molecules · doi:10.3390/molecules27092837 · Cited by 31

Enrichment of Druggable Conformations from Apo Protein Structures Using Cosolvent-Accelerated Molecular Dynamics

Kalenkiewicz, A., Grant, B. J., & Yang, C. (2015) · Biology · doi:10.3390/biology4020344 · Cited by 29

Aromatic Oligoamide Foldamers with a “Wet Edge” as Inhibitors of the α‐Helix‐Mediated p53–hDM2 Protein–Protein Interaction

Prabhakaran, P., Barnard, A., Murphy, N. S., Kilner, C. A., Edwards, T. A., & Wilson, A. J. (2013) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201300069 · Cited by 28

Conformational Plasticity of the Essential Membrane-associated Mannosyltransferase PimA from Mycobacteria

Giganti, D. O., Alegre‐Cebollada, J., Urresti, S., Albesa-Jové, D., Rodrigo‐Unzueta, A., Comino, N., Kachala, M., López‐Fernández, S., Svergun, D. I., Fernández, J. M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.462705 · Cited by 27

From Medicinal Chemistry to Human Health: Current Approaches to Drug Discovery for Cancer and Neglected Tropical Diseases

Ferreira, L. L. G., Oliva, G., & Andricopulo, A. D. (2018) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201820170505 · Cited by 26

Drug combinatorics and side effect estimation on the signed human drug-target network

Torres, N. B., & Altafini, C. (2016) · BMC Systems Biology · doi:10.1186/s12918-016-0326-8 · Cited by 27

Hybrid Mass Spectrometry Approaches to Determine How L-Histidine Feedback Regulates the Enzyzme MtATP-Phosphoribosyltransferase

Pacholarz, K. J., Burnley, R. J., Jowitt, T. A., Ordsmith, V., Pisco, J. P., Porrini, M., Larrouy-Maumus, G. J., Garlish, R. A., Taylor, R. J., de Carvalho, L. P. S., et al. (2017) · Structure · doi:10.1016/j.str.2017.03.005 · Cited by 25

Exploiting the MDM2-CK1α Protein-Protein Interface to Develop Novel Biologics That Induce UBL-Kinase-Modification and Inhibit Cell Growth

Huart, A.-S., MacLaine, N. J., Narayan, V., & Hupp, T. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043391 · Cited by 27

Natural product-inspired strategies towards the discovery of novel bioactive molecules

Gagare, S. S., Patil, P., & Jain, A. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00627-z · Cited by 26

Imidazole Nitrogens of Two Histidine Residues Participating in N–H···N Hydrogen Bonds in Protein Structures: Structural Bioinformatics Approach Combined with Quantum Chemical Calculations

Iyer, A. H., Deepak, R. N. V. K., & Sankararamakrishnan, R. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b11737 · Cited by 24

From Determinants of RUNX1/ETO Tetramerization to Small-Molecule Protein–Protein Interaction Inhibitors Targeting Acute Myeloid Leukemia

Metz, A., Schanda, J., Grez, M., Wichmann, C. W., & Gohlke, H. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400332e · Cited by 23

Design of Drug‐Like Protein–Protein Interaction Stabilizers Guided By Chelation‐Controlled Bioactive Conformation Stabilization

Bosica, F., Andrei, S. A., Neves, J. F., Brandt, P., Gunnarsson, A., Landrieu, I., Ottmann, C., & O'Mahony, G. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202001608 · Cited by 24

Which cryptic sites are feasible drug targets?

Lazou, M., Kozakov, D., Joseph‐McCarthy, D., & Vajda, S. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104197 · Cited by 23

Novel Physics-Based Ensemble Modeling Approach That Utilizes 3D Molecular Conformation and Packing to Access Aqueous Thermodynamic Solubility: A Case Study of Orally Available Bromodomain and Extraterminal Domain Inhibitor Lead Optimization Series

Hong, R. S., Mattei, A., Sheikh, A. Y., Bhardwaj, R. M., Bellucci, M. A., McDaniel, K. F., Pierce, M. O., Sun, G., Li, S., Wang, L., et al. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01410 · Cited by 23

Chemoisosterism in the Proteome

Jalencas, X., & Mestres, J. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci3002974 · Cited by 22

Structural conservation of druggable hot spots in protein–protein interfaces

Kozakov, D., Hall, D. R., Chuang, G., Cencic, R., Brenke, R., Grove, L. E., Beglov, D., Pelletier, J., Whitty, A., & Vajda, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101835108 · Cited by 245

Finding Small Molecule Ligands for Protein-Protein Interactions and Other “Undruggable” Targets

Arkin, M. R. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2009.12.2216

Protein Flexibility: A Challenging Issue of Drug Discovery

Gupta, S. P. (2018) · Current Chemical Biology · doi:10.2174/2212796812666180524100212 · Cited by 3

Emerging Target Families: Intractable Targets

Knapp, S. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_28 · Cited by 9

How Different are Structurally Flexible and Rigid Binding Sites? Sequence and Structural Features Discriminating Proteins that Do and Do not Undergo Conformational Change upon Ligand Binding

Gunasekaran, K., & Nussinov, R. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.09.062 · Cited by 144